Skip to main content

Table 3 Variables of oxidative stress between the groups (n-3 and placebo) and times (pre-exercise and post-exercise)

From: Effects of n-3 fatty acids and exercise on oxidative stress parameters in type 2 diabetic: a randomized clinical trial

 

n-3 PUFA (n = 15)

Placebo (n = 15)

 

Baseline

Follow-up

Baseline

Follow-up

 

Pre-exercise

Post-exercise

Pre-exercise

Post-exercise

Pre-exercise

Post-exercise

Pre-exercise

Post-exercise

P value*

us-CRP (mg/dL)

2.88 ± 3.2

3.10 ± 3.35

2.37 ± 2.42

2.56 ± 2.66

3.36 ± 3.39

3.63 ± 3.61

3.19 ± 3.26

3.43 ± 3.51

 

Log us-PCR (mg/dL)a

0.50 ± 0.29

0.53 ± 0.3

0.45 ± 0.28

0.47 ± 0.28

0.51 ± 0.28

0.49 ± 0.27

0.53 ± 0.29

0.50 ± 0.29

0.712

Diff. Mean (95% CI)

0.02 (0.01 to 0.03)

0.02 (0.01 to 0.04)

0.03 (0.01 to 0.04)

0.02 (0.01 to 0.03)

 

Cohen’s d

0.10

0.07

0.07

0.10

 

TBARS (pmolTBARS/mgPTN)

40.2 ± 20.9

36.7 ± 17

29.7 ± 9.9

32.5 ± 11.8

38.4 ± 19.2

40.0 ± 20.5

37.5 ± 17.7

33.1 ± 11.8

0.052

Diff. Mean (95% CI)

−3.8 (− 10 to 2.4)

− 2.9 (−1.6 to 7.4)

1.62 (− 1.03 to 4.28)

−4.4 (− 10.7 to 1.8)

 

Cohen’s d

0.18

0.26

0.08

0.28

 

F2-isoprostanes (ng/mL)

325.9 ± 314.5

262.2 ± 113

267 ± 124.9

255.1 ± 134.1

284.5 ± 190.1

319.9 ± 149.1

282.1 ± 147.3

226.1 ± 114.4

 

Log F2-isoprostanes (ng/mL)a

2.4 ± 0.39

2.36 ± 0.26

2.34 ± 0.34

2.32 ± 0.32

2.37 ± 0.29

2.45 ± 0.25

2.37 ± 0.28

2.30 ± 0.2

0.438

Diff. Mean (95% CI)

−0.05 (− 0.19 to 0.10)

−0.02 (− 0.19 to 0.16)

0.08 (− 0.05 to 0.21)

−0.07 (− 0.18 to 0.04)

 

Cohen’s d

0.12

0.06

0.26

0.28

 

Uric Acid (mg/L)

47.5 ± 16.0

48.6 ± 17.7

47.9 ± 19.1

46.9 ± 17.2

38.6 ± 8.1

39.8 ± 7.0

36.2 ± 6.9

36.6 ± 7.3

 

Log Uric Acid (mg/L)b

6.71 ± 0.91

6.77 ± 1.05

6.70 ± 1.12

6.64 ± 0.99

6.24 ± 0.71

6.36 ± 0.74

6.04 ± 0.64

6.09 ± 0.74

0.639

Diff. Mean (95% CI)

0.06 (− 0.14 to 0.26)

−0.06 (− 0.19 to 0.08)

0.12 (− 0.13 to 0.38)

0.04 (− 0.13 to 0.22)

 

Cohen’s d

0.06

0.06

0.17

0.07

 

TRAP (contains/min)

148,779 ± 51,653

158,420 ± 51,275

182,404 ± 29,313

148,520 ± 31,339

168,614 ± 36,302

166,249 ± 44,925

152,720 ± 347,681

155,678 ± 42,763

0.023

Diff. Mean (95% CI)

9641 (− 20,068 to 39,351)

−33,884 (− 56,976 to − 10,793)**

− 2366 (− 29,426 to 24,695)

2957 (−20,724 to 26,639)

 

Cohen’s d

0.19

1.12

0.06

0.01

 

SOD (USOD/mgPTN)

1.90 ± 0.99

2.44 ± 1.34

4.04 ± 2.33

4.60 ± 2.62

3.08 ± 1.74

3.06 ± 1.34

3.30 ± 1.23

3.90 ± 1.75

 

Log SOD (USOD/mgPTN)b

1.34 ± 0.36

1.52 ± 0.38

1.96 ± 0.60

2.06 ± 0.57

1.68 ± 0.37

1.70 ± 0.29

1.77 ± 0.32

1.90 ± 0.42

0.095

Diff. Mean (95% CI)

0.18 (− 0.05 to 0.41)

0.11 (− 0.46 to 0.67)

0.02 (− 0.23 to 0.26)

0.13 (−0.20 to 0.45)

 

Cohen’s d

0.49

0.17

0.06

0.34

 
  1. Values are presented as mean ± standard deviation. * Models were adjusted for age, gender, duration of diabetes and use of drugs, a Logarithmic transformation, b Square root transformation, ** p = 0.004 compared to before supplementation
  2. Abbreviations: hs-CRP high sensitivity C-reactive protein, TBARS thiobarbituric acid reactive substances, SOD superoxide dismutase
  3. p value in bold was statiscally significant
Back to article page

Journal of the International Society of Sports Nutrition

ISSN: 1550-2783

Contact us